Zimmer Biomet Names New Senior VP of Investor Relations

Zimmer Biomet has appointed David DeMartino as its new senior vice president of investor relations. DeMartino will take office on September 9, 2024.
 
Before joining Zimmer Biomet, DeMartino was chief strategy officer at Nyxoah, a company that develops and sells obstructive sleep apnea (OSA) solutions. He was also a portfolio manager at DNB Asset Management and has served in senior roles at Velan Capital, Citadel, and Pura Vida Investments. These firms covered the medical device, biotech, and healthcare technology markets.
 
DeMartino spent several years in sell-side equity research, as well. He first covered healthcare facilities at Deutsche Bank and medical devices at Credit Suisse. His career began at the Deutsche Bank Healthcare investment banking group.
 
“We are excited to welcome David to Zimmer Biomet as our head of investor relations,” said Zimmer Biomet CEO Ivan Tornos. “His impressive career achievements and extensive knowledge of the medtech industry, as both an investor and in equity research, make him the ideal candidate for this strategically important position. As we navigate an exciting and pivotal time for our Company, David will play a critical role in leading our IR initiatives and enhancing our positive relationships across the investment community.”
 
Last month, Zimmer Biomet began a deal to acquire OrthoGrid, a privately-held company that specializes in artificial intelligence (AI)-driven surgical guidance systems for total hip replacement.